|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety and efficacy of delayed re- lease rabeprazole in 1 - to 11 - month - old infants with symptomatic GERD 显示文摘 | Hussain S Kierkus J Hu P | 2014 | J Pediatr Gastroenterol Nutr2014，58，2： | 1 |
| 2 | Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children显示文摘 | Ksiazyk J Piena M Kierkus J | 2002 | J Pediatr Gastroenterol Nutr2002，35，5： | 1 |
| 3 | High-versus low-volume polyethylene glycol plus laxative versus sennosides for colonosco- py preparation in children 显示文摘 | Kierkus J Horvath A Szychta M | 2013 | J Pediatr Gastroenterol Nutr2013，57，2： | 1 |
| 4 | Safety and Efficacy of Adalimumab for Moderate to Severe Crohn’s Disease in Children显示文摘 | Jeffrey S. Hyams Anne Griffiths James Markowitz Robert N. Baldassano William A. Faubion Richard B. Colletti Marla Dubinsky Jaroslaw Kierkus Joel Rosh Yaqin Wang Bidan Huang Barry Bittle Michael Marshall Andreas Lazar | 2012 | Gastroenterology2012，，2： | 1 |
| 5 | Chemical recycling of polyurethanes and applications for the recyelates显示文摘 | You K K Durocher D T Kierkus P C | 1998 | J Cell Plast1998，34，3： | 1 |
| 6 | Hydrolyzed versus nonhy- drolyzed protein diet in short bowel syndrome in children显示文摘 | KSIAZYK J PIENA M KIERKUS J | 2002 | J Pedlatr Gastroenterol Nutr2002，35，5： | 1 |
| 7 | Chemical Recycling of Polyurethanes and Applications for the Recyclates显示文摘 | You K K Durocher D T Kierkus P Ch Fishback T L | 1998 | Journal of Cellular Plastics1998，34，3： | 1 |
| 8 | Modeling of fraction solid for 319 Aluminum alloy显示文摘 | Djurdjevic M B Kierkus W T Byczynski G E | 1999 | ASF Transactions1999，14，： | 1 |
| 9 | Histological healing after infliximab induction therapy in children with ulcerative colitis显示文摘AIM: To verify the impact of induction therapy with infliximab(IFX) on mucosal healing in children with ulcerative colitis(UC).METHODS: The study included all UC pediatric patients treated with IFX at our center over the last10 years. The data were collected from patients' medical charts and analyzed retrospectively. A total of 16 patients with UC underwent colonoscopy with sample collection before and after three IFX injections.Pediatric Ulcerative Colitis Activity Index(PUCAI)was used to assess the clinical condition; endoscopic features were classified according to the Baron scale;and histological changes were evaluated according to the protocol of The British Society of Gastroenterology and Geboes Index. Clinical response was defined as a ≥ 20-point reduction in PUCAI index, and clinical remission as PUCAI index < 10 points. Endoscopic mucosal remission was defined as completely normal(score 0) on the Baron scale. Histological remission was defined as grade 0 in the Geboes Index. To assess correlation between variables, Spearman's rank correlation coefficient was used.RESULTS: Clinical remission(PUCAI < 10) at week 8 was achieved in 68.75% of investigated subjects. Endoscopic mucosal remission at week 8(Baron 0) was observed in 12.5% of patients. Histological remission(Geboes 0)after induction therapy with IFX was noticed in 18.75%cases. A general histological improvement, expressedby normal surface and crypt architecture, number of crypts, and lamina propria cellularity, was observed in six(37.5%) patients; there was no improvement in nine(56.25%) individuals, and worsening was observed in one(3.75%) case. Changes were not related to UC location. A reduction of inflammatory process was observed in 10(62.5%) patients; there were no changes in four(25%) individuals, and the inflammation became more severe in two(12.5 %) cases. Simultaneous clinical, endoscopic and histological improvement of parameters assessing disease activity at week 8 was noticed in six(37.5%) patients. 55.5% of investigated patients with normal mucosa seen on endoscopy showed no inflammation on histology. A Baron score of 2 and 3showed a good correlation with histology results(78.2%of patients with a Geboes Index ≥ 3).CONCLUSION: IFX has a positive histological effect in more than one-third of UC patients. IFX reduces intestinal inflammation and improves clinical condition. | Anna Wiernicka Sylwia Szymanska Joanna Cielecka-Kuszyk Maciej Dadalski Jaroslaw Kierkus | 2015 | World Journal of Gastroenterology2015，21，37： | 1 |
| 10 | Hydrolyzed Versus Nonhydrolyzed Protein Diet in Short Bowel Syndrome in Children显示文摘 | Janusz Ksiazyk Marjolein Piena Jaroslaw Kierkus Malgorzata Lyszkowska | 2002 | Journal of Pediatric Gastroenterology and Nutrition2002，，5： | 1 |
| 11 | Determining dendrite coherency point characteristics of Al alloys using single-thermocouple technique显示文摘 | Jiang H Kierkus W T Sokolowski J H | 1999 | ASF Transactions1999，68，： | 1 |
| 12 | Modeling of Fraction Solid for A319 Aluminum Alloy显示文摘 | DJURDJIEVIC M B KIERKUS WT BYCZYNSKI G E | 1999 | AFS Trans1999，6，： | 1 |
| 13 | Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease:A cross-sectional study显示文摘BACKGROUND It has been suggested that apolipoprotein E(APOE)polymorphisms are associated with the risk of developing inflammatory bowel disease(IBD)and the early age of disease onset.However,there are no reports regarding the relationship with clinical characteristics and disease severity.AIM To summarise that APOE polymorphisms are associated with the risk of developing IBD and the early age of disease onset.METHODS In total,406 patients aged 3-18 with IBD(192 had ulcerative colitis and 214 had Crohn’s disease)were genotyped using the TaqMan hydrolysis probe assay.Clinical expression was described at diagnosis and the worst flare by disease activity scales,albumin and C-reactive protein levels,localisation and behaviour(Paris classification).Systemic steroid intake with the total number of courses,immunosuppressive,biological,and surgical treatment with the time and age of the first intervention were determined.The total number of exacerbation-caused hospitalisations,the number of days spent in hospital due to exacerbation,the number of relapses,and severe relapses were also estimated.RESULTS Ulcerative colitis patients with the APOEε4 allele had lower C-reactive protein values at diagnosis(P=0.0435)and the worst flare(P=0.0013)compared to patients with the APOEε2 allele and genotype APOEε3/ε3.Crohn’s disease patients with the APOEε2 allele scored lower on the Pediatric Crohn’s Disease Activity Index at diagnosis(P=0.0204).IBD patients with APOEε2 allele spent fewer days in the hospital due to relapse(P=0.0440).CONCLUSION APOE polymorphisms are associated with the risk of developing IBD and the clinical expression of IBD.However,the clinical relevance of the differences identified is rather modest. | Aleksandra Glapa-Nowak Mariusz Szczepanik Barbara Iwańczak Jarosław Kwiecień Anna Barbara Szaflarska-Popławska Urszula Grzybowska-Chlebowczyk Marcin Osiecki Marcin Dziekiewicz Andrzej Stawarski Jarosław Kierkuś Tomasz Banasiewicz Aleksandra Banaszkiewicz Jarosław Walkowiak | 2021 | World Journal of Gastroenterology2021，27，14： | 0 |
| 14 | Biosimilars in paediatric inflammatory bowel disease显示文摘The introduction of biological treatments has changed disease outcomes for patients with inflammatory bowel disease. Biologicals have high efficacy, and can induce and maintain remission after failed responses to conventional immunosuppressive and/or steroid therapy. The increasing occurrence of severe disease at diagnosis has resulted in infliximab being more often introduced as the firstline treatment in a 'top-down' approach. Besides their favourable efficacy and safety profile, biologicals have one significant disadvantage, which is their high cost. This results in many patients stopping therapy prematurely, with the maintenance phase being too short. This often leads to disease exacerbation shortly after treatment cessation. Every newly started course of biological therapy can induce production of anti-drug antibodies, which can result in treatment failure and possible allergic/anaphylactic reactions. The introduction of biological biosimilars was intended to greatly reduce therapy costs thus increasing the availability of these agents to more patients. It was also anticipated that biosimilars would prevent premature termination of therapy. Analyses of paediatric data suggest that biosimilar infliximabs are equally effective as the reference infliximab. Safety patterns also seem to be similar. Paediatric experience places costtherapy reductions at around 10%-30%. | Joanna Sieczkowska-Golub Dorota Jarzebicka Grzegorz Oracz Jaroslaw Kierkus | 2018 | World Journal of Gastroenterology2018，24，35： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员